Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

470
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
470
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

708
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
708
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

821
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
821
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

679
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
679
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

471
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
471

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glycolysis-inhibiting tumor cell-derived microparticles to enhance immunogenic cell death for synergistic cancer immunotherapy.

Biomaterials·2025
Same author

Peptide nanonet trapping suppresses bacterial motility and delays antibiotic resistance emergence.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2025
Same author

Antimicrobial peptide-conjugated graphene coatings for prevention and treatment of bacterial infections.

Nanoscale·2025
Same author

Controlling Nanonet Morphology via Residue-Specific Modulation of β-Hairpin Peptide for Enhanced Bacterial Trapping.

Small (Weinheim an der Bergstrasse, Germany)·2025
Same author

Bacterial clustering biomaterials as anti-infective therapies.

Biomaterials·2024
Same author

Structure-Guided Bacteria Specificity and Wide Activity Spectrum of Endotoxin-Responsive Peptide Nanonets.

Nano letters·2024

Related Experiment Video

Updated: Oct 13, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K

Developing inhaled protein therapeutics for lung diseases.

Abigail A Matthews1, Pui Lai Rachel Ee2,3, Ruowen Ge1

  • 1Department of Biological Sciences, Faculty of Science, National University of Singapore, 16 Science drive 4, Singapore, 117558 Singapore.

Molecular Biomedicine
|November 12, 2021
PubMed
Summary

Inhaled protein therapeutics offer targeted lung delivery for lung diseases, improving efficacy and reducing side effects compared to intravenous injections. This review explores challenges and solutions for effective inhaled biologic drug design.

Keywords:
BiologicsDrug deliveryInhalationLung diseasesProteins

More Related Videos

Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

11.1K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K

Related Experiment Videos

Last Updated: Oct 13, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K
Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

11.1K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K

Area of Science:

  • Pulmonary Drug Delivery
  • Biopharmaceutical Engineering
  • Respiratory Medicine

Background:

  • Systemic administration of biologic therapeutics (protein/polypeptide drugs) via intravenous injection for lung diseases results in low target site accumulation and potential systemic side effects.
  • Topical delivery of protein drugs to the lung via inhalation offers a more effective strategy, enhancing lung drug retention and efficacy while minimizing off-target toxicity.

Purpose of the Study:

  • To review critical considerations and challenges in designing inhaled protein therapeutics for local lung delivery.
  • To discuss potential strategies for overcoming identified issues in inhaled protein drug development.

Main Methods:

  • Literature review of current research on inhaled protein therapeutics.
  • Analysis of factors influencing drug deposition, clearance, stability, and immunogenicity.
  • Examination of inhalation device selection and its impact on drug delivery.

Main Results:

  • Inhalation provides direct lung targeting, improving drug concentration at the disease site.
  • Key challenges include optimizing drug deposition in diseased lungs, managing clearance mechanisms, and ensuring protein stability and minimizing immunogenicity.
  • Inhalation device choice significantly impacts drug distribution and lung accumulation.

Conclusions:

  • Inhaled protein therapeutics represent a promising approach for treating lung diseases, offering improved efficacy and safety profiles.
  • Addressing challenges related to drug delivery, stability, and immune response is crucial for successful clinical translation.
  • Further research into inhalation device technology and formulation strategies is warranted to optimize inhaled biologic therapies.